Loading...

Ultra-LEAF™ Purified anti-mouse CD3ε Antibody Ultra-LEAF™ Purified anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_LEAF_021606
C57BL/6 mouse splenocytes were stained with LEAF™ purified CD3e (clone 145-2C11) (filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by anti-Armenian hamster IgG FITC.
  • 145-2C11_LEAF_021606
    C57BL/6 mouse splenocytes were stained with LEAF™ purified CD3e (clone 145-2C11) (filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by anti-Armenian hamster IgG FITC.
Compare all formats
Cat # Size Price Quantity Check Availability Save
100339 100 µg DKK375
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100340 1 mg DKK975
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100359 5 mg DKK3464
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100360 25 mg DKK8364
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100371 50 mg DKK13983
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100372 100 mg DKK20096
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2025. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level
Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
IHC-F, IP, Activ, Block, WB, ICC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume or 100 µl of whole blood.  It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Additional Product Notes

Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…

View more applications data for this product in our Scientific Poster Library.

Application References
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Mirji G, et al. 2022. Sci Immunol. 7:eabn0704. PubMed
  2. Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed
  3. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  4. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  5. Guo L, et al. 2023. Sci Signal. 16:eadd4900. PubMed
  6. Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed
  7. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  8. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  9. Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed
  10. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  11. Wang T, et al. 2023. Commun Biol. 6:613. PubMed
  12. Roy S, et al. 2023. J Clin Invest. 133:. PubMed
  13. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  14. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  15. Jairaman A, et al. 2021. Bio Protoc. 11:e4170. PubMed
  16. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  17. Kwon H, et al. 2022. Sci Immunol. 7:eabq2630. PubMed
  18. Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed
  19. Chen J, et al. 2022. Neoplasma. 69:1129. PubMed
  20. Krishnamurty AT, et al. 2022. Nature. 611:148. PubMed
  21. Zhang H, et al. 2022. J Clin Invest. 132: . PubMed
  22. Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed
  23. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  24. Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed
  25. Romine KA, et al. 2023. Leukemia. 37:580. PubMed
  26. Pitmon E, et al. 2023. PLoS One. 18:e0280916. PubMed
  27. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  28. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  29. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  30. Duong–Ly KC, et al. 2018. J Cell Sci. 131:17. PubMed
  31. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  32. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  33. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  34. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  35. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  36. Donado CA, et al. 2020. Cell Reports. 31(1):107466. PubMed
  37. Zhao X, et al. 2021. Int J Oral Sci. 13:31. PubMed
  38. Wang W, et al. 2020. Cell Rep. 107936:32. PubMed
  39. Krone A, et al. 2022. Sci Rep. 218:. PubMed
  40. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  41. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  42. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  43. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  44. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  45. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  46. Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed
  47. Dong L, et al. 2017. Sci Rep. 10.1038/srep36598. PubMed
  48. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  49. Hoover DB, et al. 2020. Int Immunopharmacol. 106359:81. PubMed
  50. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  51. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  52. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  53. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  54. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  55. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  56. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  57. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  58. Gandhi VD, et al. 2022. J Clin Invest. 132:. PubMed
  59. Herrera FG, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  60. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  61. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  62. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  63. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  64. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  65. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  66. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  67. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  68. Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed
  69. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  70. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  71. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  72. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
  73. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  74. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  75. Woo MS, et al. 2021. J Exp Med. :218. PubMed
  76. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  77. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  78. Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed
  79. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  80. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  81. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  82. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  83. Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed
  84. Pandit M, et al. 2022. Exp Mol Med. 54:1214. PubMed
  85. Guo Z, et al. 2022. Neurobiol Pain. 12:100096. PubMed
  86. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  87. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  88. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  89. Wang F, et al. 2021. Nat Commun. 12:1378. PubMed
  90. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  91. Mirji G, et al. 2022. Sci Immunol. 7:eabn0704. PubMed
  92. Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed
  93. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  94. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  95. Guo L, et al. 2023. Sci Signal. 16:eadd4900. PubMed
  96. Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed
  97. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  98. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  99. Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed
  100. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  101. Wang T, et al. 2023. Commun Biol. 6:613. PubMed
  102. Roy S, et al. 2023. J Clin Invest. 133:. PubMed
  103. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  104. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  105. Jairaman A, et al. 2021. Bio Protoc. 11:e4170. PubMed
  106. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  107. Kwon H, et al. 2022. Sci Immunol. 7:eabq2630. PubMed
  108. Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed
  109. Chen J, et al. 2022. Neoplasma. 69:1129. PubMed
  110. Krishnamurty AT, et al. 2022. Nature. 611:148. PubMed
  111. Zhang H, et al. 2022. J Clin Invest. 132: . PubMed
  112. Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed
  113. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  114. Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed
  115. Romine KA, et al. 2023. Leukemia. 37:580. PubMed
  116. Pitmon E, et al. 2023. PLoS One. 18:e0280916. PubMed
  117. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  118. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  119. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  120. Duong–Ly KC, et al. 2018. J Cell Sci. 131:17. PubMed
  121. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  122. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  123. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  124. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  125. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  126. Donado CA, et al. 2020. Cell Reports. 31(1):107466. PubMed
  127. Zhao X, et al. 2021. Int J Oral Sci. 13:31. PubMed
  128. Wang W, et al. 2020. Cell Rep. 107936:32. PubMed
  129. Krone A, et al. 2022. Sci Rep. 218:. PubMed
  130. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  131. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  132. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  133. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  134. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  135. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  136. Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed
  137. Dong L, et al. 2017. Sci Rep. 10.1038/srep36598. PubMed
  138. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  139. Hoover DB, et al. 2020. Int Immunopharmacol. 106359:81. PubMed
  140. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  141. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  142. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  143. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  144. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  145. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  146. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  147. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  148. Gandhi VD, et al. 2022. J Clin Invest. 132:. PubMed
  149. Herrera FG, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  150. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  151. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  152. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  153. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  154. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  155. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  156. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  157. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  158. Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed
  159. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  160. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  161. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  162. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
  163. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  164. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  165. Woo MS, et al. 2021. J Exp Med. :218. PubMed
  166. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  167. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  168. Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed
  169. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  170. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  171. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  172. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  173. Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed
  174. Pandit M, et al. 2022. Exp Mol Med. 54:1214. PubMed
  175. Guo Z, et al. 2022. Neurobiol Pain. 12:100096. PubMed
  176. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  177. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  178. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  179. Wang F, et al. 2021. Nat Commun. 12:1378. PubMed
  180. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_11150783 (BioLegend Cat. No. 100339)
AB_11149115 (BioLegend Cat. No. 100340)
AB_2616673 (BioLegend Cat. No. 100359)
AB_2616674 (BioLegend Cat. No. 100360)
AB_2800555 (BioLegend Cat. No. 100371)
AB_2800556 (BioLegend Cat. No. 100372)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Other Formats

View All CD3ε Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε (Maxpar® Ready) 145-2C11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 510™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 605™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 711™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 785™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 750 anti-mouse CD3ε 145-2C11 FC
GoInVivo™ Purified anti-mouse CD3ε 145-2C11 FC
APC anti-mouse CD3ε 145-2C11 FC
Biotin anti-mouse CD3ε 145-2C11 FC,IHC-F
FITC anti-mouse CD3ε 145-2C11 FC
PE anti-mouse CD3ε 145-2C11 FC
PE/Cyanine5 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Alexa Fluor® 488 anti-mouse CD3ε 145-2C11 FC
Alexa Fluor® 647 anti-mouse CD3ε 145-2C11 FC,IHC-F,3D IHC
PerCP anti-mouse CD3ε 145-2C11 FC
PerCP/Cyanine5.5 anti-mouse CD3ε 145-2C11 FC
APC/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Pacific Blue™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 421™ anti-mouse CD3ε 145-2C11 FC,ICC
Ultra-LEAF™ Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Spark YG™ 593 anti-mouse CD3 145-2C11 FC
PerCP/Fire™ 780 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 650™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 750™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 810 anti-mouse CD3ε Antibody 145-2C11 FC
Spark YG™ 581 anti-mouse CD3ε (Flexi-Fluor™) 145-2C11 FC
Spark NIR™ 685 anti-mouse CD3ε (Flexi-Fluor™) Antibody 145-2C11 FC
PE/Fire™ 640 anti-mouse CD3ε 145-2C11
Go To Top Version: 4    Revision Date: 10/04/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_LEAF_021606
C57BL/6 mouse splenocytes were stained with LEAF™ purified CD3e (clone 145-2C11) (filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by anti-Armenian hamster IgG FITC.
  • 145-2C11_LEAF_021606
    C57BL/6 mouse splenocytes were stained with LEAF™ purified CD3e (clone 145-2C11) (filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by anti-Armenian hamster IgG FITC.
Compare all formats
Cat # Size Price Quantity Check Availability Save
100339 100 µg DKK375
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100340 1 mg DKK975
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100359 5 mg DKK3464
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100360 25 mg DKK8364
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100371 50 mg DKK13983
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100372 100 mg DKK20096
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2025. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level
Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
IHC-F, IP, Activ, Block, WB, ICC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume or 100 µl of whole blood.  It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Additional Product Notes

Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…

View more applications data for this product in our Scientific Poster Library.

Application References
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Mirji G, et al. 2022. Sci Immunol. 7:eabn0704. PubMed
  2. Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed
  3. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  4. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  5. Guo L, et al. 2023. Sci Signal. 16:eadd4900. PubMed
  6. Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed
  7. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  8. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  9. Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed
  10. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  11. Wang T, et al. 2023. Commun Biol. 6:613. PubMed
  12. Roy S, et al. 2023. J Clin Invest. 133:. PubMed
  13. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  14. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  15. Jairaman A, et al. 2021. Bio Protoc. 11:e4170. PubMed
  16. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  17. Kwon H, et al. 2022. Sci Immunol. 7:eabq2630. PubMed
  18. Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed
  19. Chen J, et al. 2022. Neoplasma. 69:1129. PubMed
  20. Krishnamurty AT, et al. 2022. Nature. 611:148. PubMed
  21. Zhang H, et al. 2022. J Clin Invest. 132: . PubMed
  22. Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed
  23. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  24. Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed
  25. Romine KA, et al. 2023. Leukemia. 37:580. PubMed
  26. Pitmon E, et al. 2023. PLoS One. 18:e0280916. PubMed
  27. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  28. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  29. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  30. Duong–Ly KC, et al. 2018. J Cell Sci. 131:17. PubMed
  31. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  32. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  33. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  34. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  35. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  36. Donado CA, et al. 2020. Cell Reports. 31(1):107466. PubMed
  37. Zhao X, et al. 2021. Int J Oral Sci. 13:31. PubMed
  38. Wang W, et al. 2020. Cell Rep. 107936:32. PubMed
  39. Krone A, et al. 2022. Sci Rep. 218:. PubMed
  40. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  41. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  42. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  43. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  44. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  45. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  46. Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed
  47. Dong L, et al. 2017. Sci Rep. 10.1038/srep36598. PubMed
  48. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  49. Hoover DB, et al. 2020. Int Immunopharmacol. 106359:81. PubMed
  50. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  51. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  52. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  53. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  54. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  55. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  56. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  57. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  58. Gandhi VD, et al. 2022. J Clin Invest. 132:. PubMed
  59. Herrera FG, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  60. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  61. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  62. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  63. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  64. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  65. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  66. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  67. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  68. Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed
  69. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  70. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  71. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  72. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
  73. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  74. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  75. Woo MS, et al. 2021. J Exp Med. :218. PubMed
  76. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  77. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  78. Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed
  79. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  80. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  81. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  82. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  83. Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed
  84. Pandit M, et al. 2022. Exp Mol Med. 54:1214. PubMed
  85. Guo Z, et al. 2022. Neurobiol Pain. 12:100096. PubMed
  86. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  87. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  88. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  89. Wang F, et al. 2021. Nat Commun. 12:1378. PubMed
  90. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  91. Mirji G, et al. 2022. Sci Immunol. 7:eabn0704. PubMed
  92. Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed
  93. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  94. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  95. Guo L, et al. 2023. Sci Signal. 16:eadd4900. PubMed
  96. Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed
  97. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  98. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  99. Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed
  100. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  101. Wang T, et al. 2023. Commun Biol. 6:613. PubMed
  102. Roy S, et al. 2023. J Clin Invest. 133:. PubMed
  103. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  104. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  105. Jairaman A, et al. 2021. Bio Protoc. 11:e4170. PubMed
  106. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  107. Kwon H, et al. 2022. Sci Immunol. 7:eabq2630. PubMed
  108. Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed
  109. Chen J, et al. 2022. Neoplasma. 69:1129. PubMed
  110. Krishnamurty AT, et al. 2022. Nature. 611:148. PubMed
  111. Zhang H, et al. 2022. J Clin Invest. 132: . PubMed
  112. Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed
  113. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  114. Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed
  115. Romine KA, et al. 2023. Leukemia. 37:580. PubMed
  116. Pitmon E, et al. 2023. PLoS One. 18:e0280916. PubMed
  117. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  118. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  119. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  120. Duong–Ly KC, et al. 2018. J Cell Sci. 131:17. PubMed
  121. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  122. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  123. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  124. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  125. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  126. Donado CA, et al. 2020. Cell Reports. 31(1):107466. PubMed
  127. Zhao X, et al. 2021. Int J Oral Sci. 13:31. PubMed
  128. Wang W, et al. 2020. Cell Rep. 107936:32. PubMed
  129. Krone A, et al. 2022. Sci Rep. 218:. PubMed
  130. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  131. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  132. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  133. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  134. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  135. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  136. Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed
  137. Dong L, et al. 2017. Sci Rep. 10.1038/srep36598. PubMed
  138. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  139. Hoover DB, et al. 2020. Int Immunopharmacol. 106359:81. PubMed
  140. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  141. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  142. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  143. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  144. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  145. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  146. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  147. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  148. Gandhi VD, et al. 2022. J Clin Invest. 132:. PubMed
  149. Herrera FG, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  150. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  151. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  152. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  153. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  154. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  155. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  156. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  157. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  158. Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed
  159. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  160. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  161. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  162. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
  163. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  164. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  165. Woo MS, et al. 2021. J Exp Med. :218. PubMed
  166. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  167. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  168. Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed
  169. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  170. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  171. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  172. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  173. Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed
  174. Pandit M, et al. 2022. Exp Mol Med. 54:1214. PubMed
  175. Guo Z, et al. 2022. Neurobiol Pain. 12:100096. PubMed
  176. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  177. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  178. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  179. Wang F, et al. 2021. Nat Commun. 12:1378. PubMed
  180. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_11150783 (BioLegend Cat. No. 100339)
AB_11149115 (BioLegend Cat. No. 100340)
AB_2616673 (BioLegend Cat. No. 100359)
AB_2616674 (BioLegend Cat. No. 100360)
AB_2800555 (BioLegend Cat. No. 100371)
AB_2800556 (BioLegend Cat. No. 100372)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Other Formats

View All CD3ε Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε (Maxpar® Ready) 145-2C11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 510™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 605™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 711™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 785™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 750 anti-mouse CD3ε 145-2C11 FC
GoInVivo™ Purified anti-mouse CD3ε 145-2C11 FC
APC anti-mouse CD3ε 145-2C11 FC
Biotin anti-mouse CD3ε 145-2C11 FC,IHC-F
FITC anti-mouse CD3ε 145-2C11 FC
PE anti-mouse CD3ε 145-2C11 FC
PE/Cyanine5 anti-mouse CD3ε 145-2C11 FC
Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Alexa Fluor® 488 anti-mouse CD3ε 145-2C11 FC
Alexa Fluor® 647 anti-mouse CD3ε 145-2C11 FC,IHC-F,3D IHC
PerCP anti-mouse CD3ε 145-2C11 FC
PerCP/Cyanine5.5 anti-mouse CD3ε 145-2C11 FC
APC/Cyanine7 anti-mouse CD3ε 145-2C11 FC
Pacific Blue™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 421™ anti-mouse CD3ε 145-2C11 FC,ICC
Ultra-LEAF™ Purified anti-mouse CD3ε 145-2C11 FC,IHC-F,IP,Activ,Block,WB,ICC
Spark YG™ 593 anti-mouse CD3 145-2C11 FC
PerCP/Fire™ 780 anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 650™ anti-mouse CD3ε 145-2C11 FC
Brilliant Violet 750™ anti-mouse CD3ε 145-2C11 FC
APC/Fire™ 810 anti-mouse CD3ε Antibody 145-2C11 FC
Spark YG™ 581 anti-mouse CD3ε (Flexi-Fluor™) 145-2C11 FC
Spark NIR™ 685 anti-mouse CD3ε (Flexi-Fluor™) Antibody 145-2C11 FC
PE/Fire™ 640 anti-mouse CD3ε 145-2C11
Go To Top Version: 4    Revision Date: 10/04/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account